JP2015523323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523323A5 JP2015523323A5 JP2015510686A JP2015510686A JP2015523323A5 JP 2015523323 A5 JP2015523323 A5 JP 2015523323A5 JP 2015510686 A JP2015510686 A JP 2015510686A JP 2015510686 A JP2015510686 A JP 2015510686A JP 2015523323 A5 JP2015523323 A5 JP 2015523323A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence number
- disease
- amino acid
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000004881 Amebiasis Diseases 0.000 claims 1
- 206010001980 Amoebiasis Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 206010007134 Candida infections Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009895 Colitis ischaemic Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010016228 Fasciitis Diseases 0.000 claims 1
- 201000006353 Filariasis Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000024781 Immune Complex disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 208000025609 Urogenital disease Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000003984 candidiasis Diseases 0.000 claims 1
- 230000007910 cell fusion Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 208000001606 epiglottitis Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000021760 high fever Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000010849 intracranial embolism Diseases 0.000 claims 1
- 201000008222 ischemic colitis Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 208000008494 pericarditis Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010035653 pneumoconiosis Diseases 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000005060 thrombophlebitis Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 238000009423 ventilation Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018108788A JP6923485B2 (ja) | 2012-05-11 | 2018-06-06 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120050533 | 2012-05-11 | ||
| KR20120050529 | 2012-05-11 | ||
| KR10-2012-0050533 | 2012-05-11 | ||
| KR10-2012-0050529 | 2012-05-11 | ||
| KR20120071989 | 2012-07-02 | ||
| KR10-2012-0071989 | 2012-07-02 | ||
| KR10-2012-0104144 | 2012-09-19 | ||
| KR10-2012-0104207 | 2012-09-19 | ||
| KR20120104144 | 2012-09-19 | ||
| KR20120104207 | 2012-09-19 | ||
| PCT/EP2013/055327 WO2013167298A1 (en) | 2012-05-11 | 2013-03-15 | Anti-inflammatory peptides and composition comprising the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018108788A Division JP6923485B2 (ja) | 2012-05-11 | 2018-06-06 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523323A JP2015523323A (ja) | 2015-08-13 |
| JP2015523323A5 true JP2015523323A5 (enExample) | 2016-05-12 |
| JP6466833B2 JP6466833B2 (ja) | 2019-02-06 |
Family
ID=47882179
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510686A Active JP6466833B2 (ja) | 2012-05-11 | 2013-03-15 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2015510786A Active JP6294306B2 (ja) | 2012-05-11 | 2013-05-07 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2017174211A Active JP6546232B2 (ja) | 2012-05-11 | 2017-09-11 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2018108788A Active JP6923485B2 (ja) | 2012-05-11 | 2018-06-06 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2019114719A Active JP7007333B2 (ja) | 2012-05-11 | 2019-06-20 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2021165541A Active JP7449909B2 (ja) | 2012-05-11 | 2021-10-07 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2024032114A Active JP7757448B2 (ja) | 2012-05-11 | 2024-03-04 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510786A Active JP6294306B2 (ja) | 2012-05-11 | 2013-05-07 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2017174211A Active JP6546232B2 (ja) | 2012-05-11 | 2017-09-11 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2018108788A Active JP6923485B2 (ja) | 2012-05-11 | 2018-06-06 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2019114719A Active JP7007333B2 (ja) | 2012-05-11 | 2019-06-20 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2021165541A Active JP7449909B2 (ja) | 2012-05-11 | 2021-10-07 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2024032114A Active JP7757448B2 (ja) | 2012-05-11 | 2024-03-04 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (12) | US9527888B2 (enExample) |
| EP (2) | EP3428181B1 (enExample) |
| JP (7) | JP6466833B2 (enExample) |
| KR (5) | KR20150014483A (enExample) |
| CN (7) | CN104507961B (enExample) |
| ES (3) | ES2691070T3 (enExample) |
| TW (7) | TWI640320B (enExample) |
| WO (3) | WO2013167299A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104507961B (zh) | 2012-05-11 | 2018-08-14 | 珍白斯凯尔有限公司 | 抗炎性肽及包含其的组合物 |
| EP2875826B1 (en) | 2012-05-11 | 2017-08-23 | KAEL-GemVax Co.,Ltd | Composition for preventing or treating sepsis |
| WO2014010971A1 (ko) * | 2012-07-11 | 2014-01-16 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| EP2899201B1 (en) | 2012-09-19 | 2019-09-11 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| EP2899199B1 (en) | 2012-09-19 | 2019-07-03 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| TWI616530B (zh) * | 2012-09-19 | 2018-03-01 | 傑姆維克斯＆凱爾有限公司 | 穿膜胜肽以及包含該胜肽之共軛物及組成物（一） |
| EP3736282B1 (en) | 2012-09-19 | 2023-06-21 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| KR102258864B1 (ko) | 2013-04-19 | 2021-06-01 | 주식회사 젬백스앤카엘 | 허혈성 손상 치료 및 예방용 조성물 |
| AU2014275610B2 (en) | 2013-06-07 | 2018-06-14 | Gemvax & Kael Co., Ltd. | Biological markers useful in cancer immunotherapy |
| ES2808076T3 (es) | 2013-06-21 | 2021-02-25 | Gemvax & Kael Co Ltd | Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso |
| ES2773296T3 (es) | 2013-10-23 | 2020-07-10 | Gemvax & Kael Co Ltd | Composición para tratar y prevenir la hiperplasia prostática benigna |
| KR102359396B1 (ko) * | 2013-11-22 | 2022-02-08 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| WO2015088233A1 (ko) * | 2013-12-10 | 2015-06-18 | 주식회사 카엘젬백스 | 항산화 효과를 가지는 펩티드 및 이를 포함하는 조성물 |
| JP6367950B2 (ja) | 2013-12-17 | 2018-08-01 | ジェムバックス アンド カエル カンパニー，リミティド | 前立腺癌治療用組成物 |
| ES2908096T3 (es) * | 2014-04-11 | 2022-04-27 | Gemvax & Kael Co Ltd | Péptido con actividad inhibidora de la fibrosis y composición que lo contiene |
| WO2015167067A1 (ko) * | 2014-04-30 | 2015-11-05 | 주식회사 카엘젬백스 | 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법 |
| WO2015170790A1 (ko) * | 2014-05-09 | 2015-11-12 | 주식회사 카엘젬백스 | 허혈성 손상 치료 및 예방용 조성물 |
| KR102232319B1 (ko) * | 2014-05-09 | 2021-03-26 | 주식회사 젬백스앤카엘 | 텔로머라제 펩티드를 유효성분으로 포함하는 뇌혈관 질환 예방 또는 치료용 조성물 |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| US10835582B2 (en) | 2015-02-27 | 2020-11-17 | Gemvax & Kael Co. Ltd. | Peptide for preventing hearing loss, and composition comprising same |
| KR101662438B1 (ko) | 2015-04-07 | 2016-10-04 | 가톨릭대학교 산학협력단 | X형 구조의 dna를 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 조성물 |
| EP3288961B8 (en) * | 2015-04-27 | 2022-04-27 | MacKay Memorial Hospital | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis |
| EP3305802B1 (en) | 2015-05-26 | 2021-05-12 | Gemvax & Kael Co., Ltd. | Anti-inflammatory, anti-fibrotic and wound-healing octapeptides and compositions containing the same |
| JP6923453B2 (ja) * | 2015-07-02 | 2021-08-18 | ジェムバックス アンド カエル カンパニー，リミティド | 抗ウイルス活性効能を有するペプチド及びこれを含む組成物 |
| CN105061573B (zh) * | 2015-07-20 | 2018-08-21 | 苏州大学 | 姚虻天然抗炎症多肽cecropin-TY1及其应用 |
| KR20180064434A (ko) * | 2015-11-03 | 2018-06-14 | 주식회사 젬백스앤카엘 | 신경세포 손실 예방 및 재생 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
| WO2017116138A1 (ko) * | 2015-12-28 | 2017-07-06 | 주식회사 젬백스앤카엘 | 멜라닌 억제 기능성 펩티드 및 이를 포함하는 조성물 |
| KR101897122B1 (ko) * | 2016-03-09 | 2018-09-10 | 주식회사 바이오펩 | 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도 |
| EP3428178A4 (en) * | 2016-03-09 | 2019-09-04 | Bio Pep Co., Ltd. | PEPTIDE FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES AND USE THEREOF |
| US9943566B2 (en) | 2016-03-16 | 2018-04-17 | Geoffrey Brooks Consultants, Llc | NF-κB inhibitor composition for skin health |
| ES2949697T3 (es) * | 2016-04-07 | 2023-10-02 | Gemvax & Kael Co Ltd | Péptido que tiene efectos de aumento de la actividad telomerasa y de extensión de los telómeros, y composición que contienen el mismo |
| KR101831888B1 (ko) * | 2016-04-15 | 2018-04-16 | (주)케어젠 | 항염증 활성을 갖는 펩타이드 및 이의 용도 |
| WO2017183942A2 (ko) * | 2016-04-21 | 2017-10-26 | 주식회사 젬백스앤카엘 | 콜라겐 생성 증가 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
| WO2018014936A1 (en) * | 2016-07-18 | 2018-01-25 | Nuritas Limited | Topical compositions |
| KR102042600B1 (ko) * | 2018-02-13 | 2019-11-08 | 전북대학교산학협력단 | 항산화 및 항염증 활성을 갖는 홍갯지렁이 유래 신규 펩타이드 및 이의 이용 |
| MA52794A (fr) * | 2018-05-28 | 2021-04-14 | Jiangyin Usun Pharmaceutical Co Ltd | Nouvelle utilisation pharmaceutique |
| CN112824428B (zh) * | 2019-11-21 | 2022-08-16 | 上海医药工业研究院 | 一种治疗肺疾病的生物肽及其应用 |
| KR102354916B1 (ko) * | 2020-02-11 | 2022-01-26 | 주식회사 쓰리빅스 | 신규 펩타이드 3ps_i014 및 이의 용도 |
| KR102266613B1 (ko) * | 2020-09-21 | 2021-06-18 | 자안바이오 주식회사 | 항염증 활성을 갖는 신규한 펩티드 및 이의 용도 |
| KR102302984B1 (ko) * | 2021-06-16 | 2021-09-17 | 주식회사 쓰리빅스 | 염증성 피부 질환 예방 또는 치료용 약학조성물 |
| WO2022270478A1 (ja) * | 2021-06-21 | 2022-12-29 | 国立大学法人北海道大学 | 抗ウイルス剤 |
| CN113461776B (zh) * | 2021-07-08 | 2023-05-16 | 南京财经大学 | 一种具有预防及治疗肠炎功能的小肽及其应用 |
| US11724077B2 (en) * | 2021-07-28 | 2023-08-15 | Subhash Dhawan | Therapeutic swabs for treating upper respiratory infections |
| KR102736939B1 (ko) * | 2021-09-30 | 2024-12-03 | (주)케어젠 | 항염증 활성을 갖는 펩타이드 및 이의 용도 |
| KR102609822B1 (ko) * | 2021-10-05 | 2023-12-06 | (주)케어젠 | 항염증 활성을 갖는 펩타이드와 이의 용도 |
| CN114349821B (zh) * | 2021-12-08 | 2024-01-16 | 南方医科大学珠江医院 | 蛙皮抗氧化肽及其基因在制药和抗皱化妆品的应用 |
| KR102856378B1 (ko) | 2022-09-30 | 2025-09-08 | 주식회사 젬백스앤카엘 | 4r 타우병증의 치료 또는 예방용 펩티드 |
| AU2024285799A1 (en) * | 2023-06-08 | 2025-12-18 | Gemvax & Kael Co., Ltd. | Composition comprising gv1001 for preventing or treating periodontal diseases and disorders caused by periodontal diseases |
| EP4733310A1 (en) | 2023-06-23 | 2026-04-29 | Gemvax & Kael Co., Ltd. | Novel peptide and use thereof |
| CN116693612B (zh) * | 2023-06-28 | 2025-02-18 | 禾美生物科技(浙江)有限公司 | 一种环肽及其用途 |
| KR102800994B1 (ko) | 2023-11-06 | 2025-04-29 | 주식회사 엘지에너지솔루션 | 무음극 코팅층 및 이를 포함하는 전고체 전지 |
| CN117986337B (zh) * | 2024-02-02 | 2024-08-16 | 杭州御寿生物科技有限公司 | 一种提高免疫力的益生菌组合物以及在治疗疾病中的应用 |
| WO2026071839A1 (ko) * | 2024-09-30 | 2026-04-02 | 주식회사 젬백스앤카엘 | Gv1001 펩타이드를 포함하는 암세포의 cd47 발현 감소 및 대식세포의 식세포작용 증가용 조성물 및 이의 용도 |
| CN119320425B (zh) * | 2024-11-08 | 2025-08-05 | 深圳市第二人民医院(深圳市转化医学研究院) | 多肽aamp及其在镇痛抗炎中的应用 |
| CN119552212B (zh) * | 2025-01-26 | 2025-04-25 | 杭州康源食品科技有限公司 | 一种具有降尿酸活性的三肽lfp及其应用 |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR930001915B1 (ko) | 1990-06-27 | 1993-03-20 | 포항종합제철 주식회사 | 저온 소결 압전요업재료 제조방법 |
| HU207799B (en) | 1991-07-24 | 1993-06-28 | Beres Export Import Rt | Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis |
| EP0930876B2 (en) | 1996-07-22 | 2010-07-07 | Renovo Limited | Use of compounds that promote oestrogenic activity for acclerating the healing of skin wounds |
| US6610839B1 (en) * | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
| EA199900355A1 (ru) * | 1996-10-01 | 2000-08-28 | Джерон Корпорейшн | Теломераза обратная тринскриптаза |
| US6475789B1 (en) * | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
| WO1998051329A1 (en) | 1997-05-15 | 1998-11-19 | Chugai Seiyaku Kabushiki Kaisha | Cachexia remedy |
| KR100581990B1 (ko) | 1997-07-01 | 2006-05-23 | 캄비아 바이오시스템즈 엘엘씨 | 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도 |
| US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| US6378526B1 (en) | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| IL132406A0 (en) | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
| US6815426B2 (en) | 2001-02-16 | 2004-11-09 | E. I. Du Pont De Nemours And Company | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| US6967211B2 (en) | 2001-04-10 | 2005-11-22 | Nippon Shinyaku Co. Ltd. | Remedial agent for chronic articular rheumatism |
| BR0210904A (pt) | 2001-05-16 | 2005-08-16 | Yeda Res & Dev | Uso de inibidores de il-18 para o tratamento ou prevenção de sepse |
| US20030143228A1 (en) | 2001-10-29 | 2003-07-31 | Baylor College Of Medicine | Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen |
| US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
| WO2003064447A2 (en) * | 2002-01-29 | 2003-08-07 | Posco | Immune-modulating peptide |
| AU2003240754B2 (en) | 2002-04-10 | 2009-02-26 | Merck Serono Sa | Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
| KR20050020987A (ko) | 2002-06-12 | 2005-03-04 | 바이오겐 아이덱 엠에이 인코포레이티드 | 아데노신 수용체 길항제를 사용하여 허혈 재관류 손상을치료하는 방법 |
| WO2005000227A2 (en) | 2003-06-06 | 2005-01-06 | Intermune, Inc. | Methods of treating tnf-mediated disorders |
| EP1648490A2 (en) | 2003-06-25 | 2006-04-26 | Canbas Co., Ltd. | Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity |
| KR20050040517A (ko) | 2003-10-29 | 2005-05-03 | 주식회사 오리엔트 | 허혈성 질환에 대한 저항성을 나타내는 형질전환 생쥐 |
| ES2258694T3 (es) | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| CA2646131C (en) | 2005-03-21 | 2018-09-04 | Vicus Therapeutics Spe 1, Llc | Compositions and methods for ameliorating cachexia |
| WO2007061029A1 (ja) | 2005-11-25 | 2007-05-31 | Keio University | 前立腺癌治療剤 |
| EP1968643A2 (en) | 2005-12-16 | 2008-09-17 | Diatos | Cell penetrating peptide conjugates for delivering of nucleic acids into a cell |
| EP1969141A4 (en) * | 2005-12-23 | 2009-01-21 | Sienna Cancer Diagnostics Ltd | TEST FOR DETECTING TELOMERASE ACTIVITY |
| JP5295785B2 (ja) | 2006-02-20 | 2013-09-18 | エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション | 細胞膜透過性ペプチド |
| JP2009544688A (ja) | 2006-07-24 | 2009-12-17 | フォーヒューマンテック カンパニー リミテッド | 虚血性疾患の緩和及び治療のための医薬組成物並びにそれを伝達するための方法 |
| EP2837636B1 (en) | 2007-01-29 | 2018-04-11 | Procell Therapeutics Inc. | Novel macromolecule transduction domains and methods for identification and uses thereof |
| WO2009006439A1 (en) | 2007-06-29 | 2009-01-08 | Correlogic Systems, Inc. | Predictive markers for ovarian cancer |
| CA2695374A1 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| WO2009025871A1 (en) * | 2007-08-23 | 2009-02-26 | University Of Medicine And Dentistry Of Nj | Telomerase reverse transcriptase variant |
| WO2009054996A2 (en) | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
| GB2455539B (en) | 2007-12-12 | 2012-01-18 | Cambridge Entpr Ltd | Anti-inflammatory compositions and combinations |
| TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| US8828403B2 (en) * | 2008-06-16 | 2014-09-09 | Mediolanum Farmaceutici S.P.A. | Anti-tumor immunotherapy |
| US8252282B2 (en) | 2008-06-19 | 2012-08-28 | University Of Medicine & Dentistry Of New Jersey | Nuclear telomerase reverse transcriptase variant |
| ES2334315B1 (es) | 2008-07-29 | 2011-02-28 | Universitat Pompeu Fabra | Peptidos con capacidad de penetracion celular y sus usos. |
| CA2734487A1 (en) | 2008-08-20 | 2010-02-25 | Southern Research Institute | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| JP5337809B2 (ja) | 2008-09-22 | 2013-11-06 | 日清ファルマ株式会社 | 抗炎症性ペプチド |
| WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| KR101169030B1 (ko) | 2009-01-21 | 2012-07-26 | 애니젠 주식회사 | 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 |
| CN102405183B (zh) | 2009-04-20 | 2014-08-06 | 奥蒂斯电梯公司 | 用于乘客传送器的扶栏和盖板安装组件 |
| WO2010128807A2 (ko) | 2009-05-07 | 2010-11-11 | (주)문엔제이 | 신경손상 및 신경질환 예방 또는 치료용 약학조성물 |
| EP2251028A1 (en) | 2009-05-12 | 2010-11-17 | Biocompatibles Uk Ltd. | Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor |
| US7928067B2 (en) | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| AU2010250452B2 (en) | 2009-05-20 | 2014-06-05 | Toray Industries, Inc. | Cell membrane-permeable peptides |
| KR20110057049A (ko) | 2009-11-23 | 2011-05-31 | 박의신 | 기능성 전립선염 치료제 |
| KR20110062943A (ko) | 2009-12-04 | 2011-06-10 | 주식회사종근당 | 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제 |
| NO2524039T3 (enExample) | 2010-01-11 | 2018-04-28 | ||
| RU2581800C2 (ru) * | 2010-02-16 | 2016-04-20 | Ультимовакс Ас | Полипептиды |
| FR2960542B1 (fr) | 2010-05-27 | 2012-08-17 | Esther Suzy Arlette Fellous | Peptide en tant que medicament, en particulier pour le traitement du cancer |
| KR101263212B1 (ko) | 2010-05-28 | 2013-05-10 | 성신여자대학교 산학협력단 | 신규한 세포막 투과성 펩타이드 및 그의 용도 |
| WO2011150494A1 (en) | 2010-05-30 | 2011-12-08 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for anticancer compounds |
| KR101388372B1 (ko) | 2010-06-11 | 2014-04-23 | 한국화학연구원 | 청각보호 작용을 하는 신규 화합물 |
| KR101348284B1 (ko) | 2010-09-09 | 2014-01-03 | 주식회사 나이벡 | 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도 |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| KR20120121196A (ko) | 2011-04-26 | 2012-11-05 | 주식회사 글루칸 | 관절염 치료제 |
| KR101284772B1 (ko) | 2011-05-24 | 2013-07-17 | 정종문 | 항염증, 진통효과를 가지는 기능성 식품 조성물 |
| KR20120133661A (ko) | 2011-05-31 | 2012-12-11 | 주식회사 바이오포트코리아 | 아스타잔틴을 포함하는 항염증제 |
| KR101288053B1 (ko) | 2011-07-04 | 2013-07-23 | 동국대학교 산학협력단 | 필발 추출물을 유효성분으로 포함하는 내이손상 예방 및 치료용 조성물 |
| KR101361445B1 (ko) | 2011-12-26 | 2014-02-12 | 성균관대학교산학협력단 | 펩타이드, 5-플루오로우라실, 및 성숙수지상세포를 포함하는 암 치료용 약학적 조성물 |
| SG11201404570WA (en) | 2012-02-10 | 2014-11-27 | Hakushinkouseikai Foundation | Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine |
| WO2013135266A1 (en) | 2012-03-12 | 2013-09-19 | Gemvax As | Treatment of non-small cell lung carcinoma by active immunotherapy |
| CN104507961B (zh) | 2012-05-11 | 2018-08-14 | 珍白斯凯尔有限公司 | 抗炎性肽及包含其的组合物 |
| EP2875826B1 (en) | 2012-05-11 | 2017-08-23 | KAEL-GemVax Co.,Ltd | Composition for preventing or treating sepsis |
| WO2014010971A1 (ko) | 2012-07-11 | 2014-01-16 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| EP3736282B1 (en) | 2012-09-19 | 2023-06-21 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| KR102038487B1 (ko) | 2012-09-19 | 2019-10-30 | 주식회사 젬백스앤카엘 | 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물 |
| EP2899201B1 (en) | 2012-09-19 | 2019-09-11 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| EP2899199B1 (en) | 2012-09-19 | 2019-07-03 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| KR20140104288A (ko) | 2013-02-20 | 2014-08-28 | 주식회사 카엘젬백스 | Tnf-알파 저해제 |
| US10525075B2 (en) | 2013-02-22 | 2020-01-07 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds, compositions, methods, and kits relating to telomere extension |
| KR102258864B1 (ko) | 2013-04-19 | 2021-06-01 | 주식회사 젬백스앤카엘 | 허혈성 손상 치료 및 예방용 조성물 |
| AU2014275610B2 (en) | 2013-06-07 | 2018-06-14 | Gemvax & Kael Co., Ltd. | Biological markers useful in cancer immunotherapy |
| ES2808076T3 (es) | 2013-06-21 | 2021-02-25 | Gemvax & Kael Co Ltd | Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso |
| EP3020724A4 (en) | 2013-07-12 | 2017-01-18 | Gemvax & Kael Co., Ltd. | Cell-penetrating peptide and conjugate comprising same |
| ES2773296T3 (es) | 2013-10-23 | 2020-07-10 | Gemvax & Kael Co Ltd | Composición para tratar y prevenir la hiperplasia prostática benigna |
| KR102359396B1 (ko) | 2013-11-22 | 2022-02-08 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| JP6367950B2 (ja) | 2013-12-17 | 2018-08-01 | ジェムバックス アンド カエル カンパニー，リミティド | 前立腺癌治療用組成物 |
| ES2908096T3 (es) | 2014-04-11 | 2022-04-27 | Gemvax & Kael Co Ltd | Péptido con actividad inhibidora de la fibrosis y composición que lo contiene |
| WO2015167067A1 (ko) | 2014-04-30 | 2015-11-05 | 주식회사 카엘젬백스 | 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법 |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| US10835582B2 (en) | 2015-02-27 | 2020-11-17 | Gemvax & Kael Co. Ltd. | Peptide for preventing hearing loss, and composition comprising same |
| EP3305802B1 (en) | 2015-05-26 | 2021-05-12 | Gemvax & Kael Co., Ltd. | Anti-inflammatory, anti-fibrotic and wound-healing octapeptides and compositions containing the same |
| US20170112941A1 (en) | 2015-10-13 | 2017-04-27 | Symic Ip, Llc | Ve-cadherin binding bioconjugate |
| KR20180064434A (ko) | 2015-11-03 | 2018-06-14 | 주식회사 젬백스앤카엘 | 신경세포 손실 예방 및 재생 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
| KR20170054310A (ko) | 2015-11-09 | 2017-05-17 | 주식회사 젬백스앤카엘 | 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법 |
-
2013
- 2013-03-15 CN CN201380036618.7A patent/CN104507961B/zh active Active
- 2013-03-15 JP JP2015510686A patent/JP6466833B2/ja active Active
- 2013-03-15 EP EP18184847.4A patent/EP3428181B1/en active Active
- 2013-03-15 KR KR1020147034320A patent/KR20150014483A/ko not_active Ceased
- 2013-03-15 EP EP13713371.6A patent/EP2850097B1/en active Active
- 2013-03-15 KR KR1020227014717A patent/KR102578891B1/ko active Active
- 2013-03-15 WO PCT/EP2013/055329 patent/WO2013167299A1/en not_active Ceased
- 2013-03-15 CN CN201810794313.7A patent/CN108949717B/zh active Active
- 2013-03-15 WO PCT/EP2013/055327 patent/WO2013167298A1/en not_active Ceased
- 2013-03-15 CN CN202310636408.7A patent/CN116694597A/zh active Pending
- 2013-03-15 KR KR1020217005717A patent/KR20210025132A/ko not_active Ceased
- 2013-03-15 CN CN201810797270.8A patent/CN108841802B/zh active Active
- 2013-03-15 CN CN202211006340.6A patent/CN115927242B/zh active Active
- 2013-03-15 ES ES13713371T patent/ES2691070T3/es active Active
- 2013-03-15 ES ES18184847T patent/ES3046661T3/es active Active
- 2013-03-15 US US14/400,321 patent/US9527888B2/en active Active
- 2013-05-01 TW TW106131665A patent/TWI640320B/zh active
- 2013-05-01 TW TW102115616A patent/TWI665304B/zh active
- 2013-05-01 TW TW106131711A patent/TWI649423B/zh active
- 2013-05-01 TW TW110101563A patent/TWI784394B/zh active
- 2013-05-01 TW TW102115617A patent/TWI640632B/zh active
- 2013-05-01 TW TW107131413A patent/TWI719344B/zh active
- 2013-05-01 TW TW111127474A patent/TW202246301A/zh unknown
- 2013-05-07 US US14/400,291 patent/US9540419B2/en active Active
- 2013-05-07 WO PCT/EP2013/059460 patent/WO2013167574A1/en not_active Ceased
- 2013-05-07 CN CN201380036639.9A patent/CN104507962B/zh active Active
- 2013-05-07 ES ES17208839T patent/ES2750003T3/es active Active
- 2013-05-07 KR KR1020147006695A patent/KR102043426B1/ko active Active
- 2013-05-07 KR KR1020157011995A patent/KR101685551B1/ko active Active
- 2013-05-07 JP JP2015510786A patent/JP6294306B2/ja active Active
- 2013-05-07 CN CN201810436830.7A patent/CN108478786B/zh active Active
-
2016
- 2016-11-04 US US15/343,502 patent/US10039811B2/en active Active
- 2016-11-17 US US15/354,139 patent/US10206981B2/en active Active
-
2017
- 2017-09-11 JP JP2017174211A patent/JP6546232B2/ja active Active
-
2018
- 2018-06-06 JP JP2018108788A patent/JP6923485B2/ja active Active
- 2018-07-02 US US16/025,352 patent/US10960056B2/en active Active
- 2018-12-21 US US16/230,732 patent/US10888606B2/en active Active
-
2019
- 2019-06-20 JP JP2019114719A patent/JP7007333B2/ja active Active
-
2020
- 2020-10-26 US US17/080,653 patent/US11369665B2/en active Active
- 2020-12-04 US US17/112,935 patent/US11622998B2/en active Active
-
2021
- 2021-10-07 JP JP2021165541A patent/JP7449909B2/ja active Active
-
2022
- 2022-06-08 US US17/835,278 patent/US11857607B2/en active Active
-
2023
- 2023-02-22 US US18/172,787 patent/US12171812B2/en active Active
- 2023-08-09 US US18/446,712 patent/US12156902B2/en active Active
- 2023-08-09 US US18/447,049 patent/US12168039B2/en active Active
-
2024
- 2024-03-04 JP JP2024032114A patent/JP7757448B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015525768A5 (enExample) | ||
| JP2015521039A5 (enExample) | ||
| JP2016128513A5 (enExample) | ||
| Guo et al. | Neutralising antibodies against human metapneumovirus | |
| JP2011528896A5 (enExample) | ||
| Ibañez et al. | Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection | |
| JP2015517489A5 (enExample) | ||
| Paladini et al. | The worldwide impact of vaccination on the control and protection of viral hepatitis B | |
| JP2011528895A5 (enExample) | ||
| JP2016538885A5 (enExample) | ||
| IL288541B (en) | Vaccine against rsv | |
| SI2699601T1 (en) | PROTITOLIC POLYPETIDES AS THE CD40 ANTAGONISTS | |
| JP2016513471A5 (enExample) | ||
| WO2008103380A3 (en) | Hepatitis b virus compositions and methods of use | |
| JP2016515524A5 (enExample) | ||
| EP3308798A3 (en) | Polypeptides and antibodies for treating hbv infection and related diseases | |
| JP2013172743A5 (enExample) | ||
| GB201206559D0 (en) | Polypeptide | |
| HRP20200230T1 (hr) | Polipeptidi antitijela koji antagoniziraju cd40l | |
| JP2011528897A5 (enExample) | ||
| WO2013059559A3 (en) | Compounds and methods for enhancing innate immune responses | |
| JP2015501840A5 (enExample) | ||
| JP2008541759A5 (enExample) | ||
| JP2013523718A5 (enExample) | ||
| JP2014519817A5 (enExample) |